|
5.5.1 ASCO (général)
|
|
|
|
ASCO’s
CancerLinQ™ Extends its Reach – 58 Oncology Practices, 750,000 Patient
Records, 1,000 Providers Under Contract, New Partnership Launch With the
Nation’s Leading Cancer Informatics Association [ASCO]
|
|
|
|
|
|
CancerLinQ
has completed agreements with 58 oncology practices, representing 1,000
providers under contract in 39 states and the District of Columbia, and
continues to actively recruit practices nationwide. Participants range
from small private practices to some of the nation’s leading cancer
centers including, most recently, Intermountain Healthcare.
|
|
|
|
|
|
|
5.5.10 ASCO (hémato)
|
|
|
|
VYXEOS scores a 10 over 7+3 [The OBR Blog]
|
|
|
|
|
|
Thus,
while VYXEOS sets a high survival benchmark in elderly, high-risk AML
patients, this cytotoxic agent still leaves some room for targeted
agents such as volasertib (which targets polo-like kinase), ganetespib
(which targets heat-shock protein 90), and vadastuximab talirine (which
targets CD33) with potentially less toxicity to enter into the same
space if they too can demonstrate significant survival benefits,
although notably these drugs are all being compared with low-intensity,
single-agent therapies in their ongoing pivotal trials.
|
|
|
|
|
|
|
CASTOR Shines in Relapsed/Refractory Multiple Myeloma [The OBR Blog]
|
|
|
|
|
|
Darzalex
utilization is currently reserved for fourth-line; however, results
from the CASTOR trial are practice changing, and these data suggest that
DVd should be considered a new standard of care for relapsed/refractory
multiple myeloma patients currently receiving Vd alone.
|
|
|
|
|
|
|
|
|
|
|
|
5.5.11 ASCO (SNC]
|
|
|
|
|
|
5.5.12 ASCO (médico-éco)
|
|
|
|
|
Combination Cancer Drug Therapies Raise Cost Concerns [Wall Street Journal]
|
|
|
|
|
|
In
an interview, AbbVie Chief Executive Richard Gonzalez acknowledged the
high cost of multidrug combinations. “In the grand scheme of things,
it’s worth it” if they lead to cures or long remissions, he said. An
AbbVie spokesman said the Imbruvica-Venclexta combination is in early
clinical studies, and that no cost has been set.
|
|
|
|
|
|
|
5.5.14 ASCO (vessie)
|
|
|
|
|
|
|
5.5.15 ASCO (biopsies liquides)
|
|
|
Guardant Health Maps Cautious Plans For Blood-Based Cancer Screening [Xconomy]
|
|
|
|
|
|
Liquid
biopsies aim to find DNA fragments shed by tumor cells into the blood
stream. Proponents say this tumor DNA—referred to as circulating tumor
DNA (ctDNA) or cell free DNA—is a far more reliable indicator of cancer
than current screening methods, such as the images taken by mammography
and lung scans, or the test for prostate-specific antigen (PSA) protein
in men’s blood.
|
|
|
|
|
|
|
|
|
|
5.5.16 ASCO (médecine de précision)
|
|
|
Innovative Direct-to-Patient Outreach May Accelerate Breast Cancer Research [ASCO]
|
|
|
|
|
|
“Recruiting
thousands of patients to a study in a matter of months is a remarkable
achievement and the quantity of data obtained from patients treated in
the real-world, including information from those who responded
exceedingly well to certain treatments, could be a source of insight as
we push forward in our path towards precision therapy.”
|
|
|
|
|
|
|
|
|
|
5.5.17 ASCO (pancréas)
|
|
|
|
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
|
|
|
|
|
|
|
Copycat biotech cancer drug works as well as Roche original: study [Reuters]
|
|
|
|
|
|
In
the new study, nearly 70 percent of trial patients responded to
MYL-14010, meaning their tumors shrank, compared with a 64 percent
response rate for Herceptin. Serious side effects occurred in 38 percent
of patients treated with the biosimilar and 36 percent of patients
given Herceptin, also known as trastuzumab.
|
|
|
|
|
|
|
|
|
|
|
5.5.4 ASCO (immunothérapies)
|
|
|
|
|
|
|
|
|
5.5.5 ASCO (gastro-intestinal)
|
|
|
|
|
|
5.5.6 ASCO (peau-mélanome)
|
|
|
|
5.5.7 ASCO (gynéco)
|
|
|
|
5.5.8 ASCO (poumon)
|
|
|
|
|
|
|
|
|
|
|
|
5.5.9 ASCO (autres organes)
|
|
|
|
|